At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 87 enrolled
Drug / intervention
0.03% Bimatoprostdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
In Brief
A Phase 4 clinical trial evaluating 0.03% Bimatoprost for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 87 participants across 1 site.
Detailed Summary
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
Primary CompletionDec 2012
First PostedDec 2013
TodayJul 2026
First PostedDec 25, 2013
Enrollment StartJul 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.5 years ago
Interventions
0.03% Bimatoprostdrug
0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.